|
ES2524356T3
(es)
|
2010-07-22 |
2014-12-05 |
Gilead Sciences, Inc. |
Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
|
|
KR20160148715A
(ko)
*
|
2014-05-13 |
2016-12-26 |
에프. 호프만-라 로슈 아게 |
B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온
|
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
|
US9637485B2
(en)
*
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
HK1244281B
(zh)
*
|
2015-02-11 |
2020-02-07 |
F. Hoffmann-La Roche Ag |
治疗和预防乙型肝炎病毒感染的2-氧代-6，7-二氢苯并[a]喹嗪-3-甲酸衍生物
|
|
WO2016177655A1
(en)
|
2015-05-04 |
2016-11-10 |
F. Hoffmann-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
US10179131B2
(en)
|
2015-07-13 |
2019-01-15 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
|
WO2017016921A1
(en)
*
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
New crystalline forms of (6s)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
JP6506880B2
(ja)
|
2015-07-27 |
2019-04-24 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
|
|
WO2017017043A1
(en)
|
2015-07-28 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
|
DK3785717T3
(da)
|
2015-09-16 |
2022-03-21 |
Gilead Sciences Inc |
Fremgangsmåder til behandling af coronaviridae-infektioner
|
|
US20200270265A1
(en)
*
|
2016-02-19 |
2020-08-27 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
|
KR102398439B1
(ko)
|
2016-03-07 |
2022-05-16 |
이난타 파마슈티칼스, 인코포레이티드 |
B형 간염 항바이러스제
|
|
EA201892375A1
(ru)
|
2016-05-27 |
2019-08-30 |
Джилид Сайэнс, Инк. |
Способы лечения инфекций, вызываемых вирусом гепатита b
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
CA3028228A1
(en)
|
2016-06-10 |
2017-12-14 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
|
EP4219767A1
(en)
*
|
2016-06-17 |
2023-08-02 |
F. Hoffmann-La Roche AG |
Papd5 and papd7 inhibitors for treating a hepatitis b infection
|
|
JP7034133B2
(ja)
*
|
2016-07-14 |
2022-03-11 |
エフ．ホフマン－ラ ロシュ アーゲー |
感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物
|
|
CN107759585A
(zh)
*
|
2016-07-29 |
2018-03-06 |
银杏树药业(苏州)有限公司 |
一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
|
|
WO2018022282A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Newave Pharmaceutical Inc. |
Novel therapeutic agents for the treatment of hbv infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018041873A1
(en)
*
|
2016-09-01 |
2018-03-08 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
TW201811788A
(zh)
|
2016-09-09 |
2018-04-01 |
瑞士商諾華公司 |
作為抗病毒劑之多環吡啶酮化合物
|
|
KR20230010826A
(ko)
|
2016-10-14 |
2023-01-19 |
프리시젼 바이오사이언시스 인코포레이티드 |
B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
|
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
|
CN110088104B
(zh)
|
2016-11-03 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物
|
|
EP3535262B1
(en)
|
2016-11-03 |
2020-08-05 |
F. Hoffmann-La Roche AG |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
|
US11124495B2
(en)
|
2016-11-03 |
2021-09-21 |
Hoffmann-La Roche, Inc. |
Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infection
|
|
SG11201902944TA
(en)
*
|
2016-11-07 |
2019-05-30 |
Arbutus Biopharma Corp |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
|
CN109369640B
(zh)
|
2017-01-13 |
2020-03-27 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物的制备方法
|
|
TW202510891A
(zh)
|
2017-01-31 |
2025-03-16 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
UY37581A
(es)
|
2017-02-02 |
2018-08-31 |
Gilead Sciences Inc |
Compuestos para el tratamiento de la infección por virus de la hepatitis b
|
|
US11053260B2
(en)
*
|
2017-02-23 |
2021-07-06 |
Fujian Cosunter Pharmaceutical Co., Ltd. |
Tri-cycle compound and applications thereof
|
|
US10682368B2
(en)
|
2017-03-14 |
2020-06-16 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
AR111419A1
(es)
*
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
|
CA3059777C
(en)
|
2017-05-01 |
2023-02-21 |
Gilead Sciences, Inc. |
Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
|
CN108530449B
(zh)
*
|
2017-05-22 |
2021-05-07 |
河南春风医药科技有限公司 |
用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
|
|
CN110066278B
(zh)
|
2017-06-01 |
2021-06-08 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
WO2019014247A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
SG11202001685TA
(en)
|
2017-08-28 |
2020-03-30 |
Enanta Pharm Inc |
Hepatitis b antiviral agents
|
|
FI3692040T3
(fi)
*
|
2017-10-05 |
2023-03-29 |
Glaxosmithkline Ip Dev Ltd |
Kemiallisia yhdisteitä
|
|
CN111511914B
(zh)
|
2017-10-16 |
2023-11-17 |
豪夫迈·罗氏有限公司 |
减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
|
|
WO2019084271A1
(en)
|
2017-10-25 |
2019-05-02 |
Children's Medical Center Corporation |
PAPD5 INHIBITORS AND METHODS OF USE
|
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
|
WO2019113175A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2019113173A1
(en)
|
2017-12-06 |
2019-06-13 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
|
CA3086792A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Bayer Aktiengesellschaft |
Hydroxyisoxazolines and derivatives thereof
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
US11058678B2
(en)
|
2018-01-22 |
2021-07-13 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
EP3759110A1
(en)
|
2018-02-28 |
2021-01-06 |
Novartis AG |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
|
TWI801517B
(zh)
|
2018-03-12 |
2023-05-11 |
加拿大商愛彼特生物製藥公司 |
經取代的2-吡啶酮三環化合物、其類似物及其使用方法
|
|
WO2019191166A1
(en)
|
2018-03-29 |
2019-10-03 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
CA3096687A1
(en)
|
2018-04-12 |
2019-10-17 |
Arbutus Biopharma Corporation |
Methods for preparing substituted pyridinone-containing tricyclic compounds
|
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
PE20210346A1
(es)
|
2018-07-03 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
|
SG11202012425QA
(en)
|
2018-07-13 |
2021-01-28 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CN110862390B
(zh)
|
2018-08-28 |
2023-05-09 |
广东东阳光药业有限公司 |
稠合三环类化合物及其在药物中的应用
|
|
JP2022500466A
(ja)
|
2018-09-21 |
2022-01-04 |
エナンタ ファーマシューティカルズ インコーポレイテッド |
抗ウイルス剤としての官能化複素環
|
|
CN110964023B
(zh)
|
2018-09-30 |
2022-12-27 |
广东东阳光药业有限公司 |
稠合四环类化合物及其在药物中的应用
|
|
WO2020086556A1
(en)
|
2018-10-24 |
2020-04-30 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
US11203591B2
(en)
|
2018-10-31 |
2021-12-21 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
IL283190B2
(en)
|
2018-11-21 |
2025-08-01 |
Enanta Pharm Inc |
Functionalized heterocycles as antiviral agents
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN111410653B
(zh)
*
|
2019-01-08 |
2021-12-17 |
苏州爱科百发生物医药技术有限公司 |
一种二氢异喹啉类化合物
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
EP3959197A4
(en)
|
2019-04-24 |
2022-10-12 |
Children's Medical Center Corporation |
PAPD5 INHIBITORS AND METHODS OF USE THEREOF
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
WO2020247444A1
(en)
|
2019-06-03 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
WO2020247561A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc, |
Hepatitis b antiviral agents
|
|
WO2020247575A1
(en)
|
2019-06-04 |
2020-12-10 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antiviral agents
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
US11738019B2
(en)
|
2019-07-11 |
2023-08-29 |
Enanta Pharmaceuticals, Inc. |
Substituted heterocycles as antiviral agents
|
|
US20220257619A1
(en)
|
2019-07-18 |
2022-08-18 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
US11236108B2
(en)
|
2019-09-17 |
2022-02-01 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocycles as antiviral agents
|
|
DK4037708T3
(da)
|
2019-09-30 |
2024-09-30 |
Gilead Sciences Inc |
HBV-vacciner og fremgangsmåder til at behandle HBV
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
|
|
KR20220153619A
(ko)
|
2020-03-12 |
2022-11-18 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 뉴클레오사이드의 제조 방법
|
|
WO2021188414A1
(en)
|
2020-03-16 |
2021-09-23 |
Enanta Pharmaceuticals, Inc. |
Functionalized heterocyclic compounds as antiviral agents
|
|
WO2021188959A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
CA3172483A1
(en)
|
2020-04-06 |
2021-10-14 |
Scott Ellis |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
|
JP7706475B2
(ja)
*
|
2020-05-15 |
2025-07-11 |
福建▲広▼生中霖生物科技有限公司 |
三環式化合物を含む組み合わせ及びｈｂｖ治療薬物の製造におけるその使用
|
|
TW202203941A
(zh)
|
2020-05-29 |
2022-02-01 |
美商基利科學股份有限公司 |
瑞德西韋之治療方法
|
|
PE20230618A1
(es)
|
2020-06-24 |
2023-04-14 |
Gilead Sciences Inc |
Analogos de nucleosido de 1'-ciano y usos de los mismos
|
|
EP4192474B1
(en)
|
2020-08-07 |
2025-09-10 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
CN111943946B
(zh)
*
|
2020-08-19 |
2022-07-01 |
中国医学科学院医药生物技术研究所 |
含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
|
|
IL300412A
(en)
|
2020-08-24 |
2023-04-01 |
Gilead Sciences Inc |
Phospholipid compounds and their uses
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
WO2022241134A1
(en)
|
2021-05-13 |
2022-11-17 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022251318A1
(en)
|
2021-05-26 |
2022-12-01 |
Gilead Sciences, Inc. |
Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
AU2022328698B2
(en)
|
2021-08-18 |
2025-02-20 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
KR20240154647A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
KR20240154646A
(ko)
|
2022-03-02 |
2024-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
바이러스성 감염 치료를 위한 화합물 및 방법
|
|
KR20240155326A
(ko)
|
2022-03-03 |
2024-10-28 |
길리애드 사이언시즈, 인코포레이티드 |
항바이러스 화합물 및 이의 제조와 사용 방법
|
|
JP2025508941A
(ja)
|
2022-03-03 |
2025-04-10 |
ギリアード サイエンシーズ， インコーポレイテッド |
抗ウイルス化合物並びにその作製及び使用方法
|
|
US20240009220A1
(en)
|
2022-06-06 |
2024-01-11 |
Gilead Sciences, Inc. |
Methods for treatment of viral infections
|
|
WO2024006376A1
(en)
|
2022-06-29 |
2024-01-04 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
EP4547665A1
(en)
|
2022-06-30 |
2025-05-07 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
|
WO2024173458A1
(en)
|
2023-02-16 |
2024-08-22 |
Gilead Sciences, Inc. |
Phospholipid compounds and methods of making and using the same
|
|
US20250090537A1
(en)
|
2023-08-31 |
2025-03-20 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
AU2024330988A1
(en)
|
2023-08-31 |
2026-02-19 |
Gilead Sciences, Inc. |
Antiviral compounds and methods of making and using the same
|
|
WO2025054278A1
(en)
|
2023-09-06 |
2025-03-13 |
Gilead Sciences, Inc. |
Solid forms of a nucleoside analogue and uses thereof
|
|
US20250109157A1
(en)
|
2023-09-28 |
2025-04-03 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|